The latest research findings support Harvard's discovery: Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss
I'm PortAI, I can summarize articles.
最新研究表明，諾和諾德的減肥藥 Ozempic 與罕見的視覺損失（NAION）有關，使用該藥物的肥胖症患者被診斷出 NAION 的概率超過兩倍。儘管眼部條件的風險仍然偏低，患者應保持警惕。諾和諾德的股價一度下跌超過 3.3%。
大規模試驗結果表明：諾和諾德減肥藥 Ozempic 與罕見的視覺損失有關，支持了哈佛大學年內稍早給出的研究結果。使用 Ozempic 的肥胖症患者被診斷出 NAION 的概率超過兩倍。當血液流動減少傷害到視覺神經時，就會發生 NAION。眼部條件的風險仍然偏低；病患應當留意。諾和諾德丹麥股價一度跌超 3.3%。
風險提示及免責條款
市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見、觀點或結論是否符合其特定狀況。據此投資，責任自負。
Source: 華爾街見聞 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments